Immatics N.V. Warrants (IMTXW)
followers
·
Follow
| Sector: | |
| Industry: | |
| CEO: | Harpreet Singh-Jasuja |
| Employees: | 260 |
| Web site: | immatics.com |
|
PAUL EHRLICH-STRASSE 15, TUBINGEN, 2M, 72076
49 7071 5397 700
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Immatics N.V. focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited.